GLP1R and metabolic dysfunction-associated steatotic liver disease: Given that NAFLD is a metabolic disease, understanding how GLP-1R agonists impact the structure of biomolecules, such as proteins, lipids, and carbohydrates, could provide valuable insights into the mechanisms underlying the protective effect of these agents on steatosis and NAFLD.